Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
Open Access
- 1 January 2020
- journal article
- research article
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 28 (1) , 55-65
Abstract
Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e5. /Synapse/10.12793/tcp.2020.28.e5Keywords
Funding Information
- Yuhan Corp.
This publication has 20 references indexed in Scilit:
- The role of acid inhibition in Helicobacter pylori eradicationF1000Research, 2016
- Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover StudyAdvances in Therapy, 2016
- Beyond the stomach: An updated view ofHelicobacter pyloripathogenesis, diagnosis, and treatmentWorld Journal of Gastroenterology, 2014
- Current progress toward eradicatingHelicobacter pyloriin East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South KoreaWorld Journal of Gastroenterology, 2014
- Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised EditionHelicobacter, 2010
- Long-lasting inhibitors of the gastric H,K-ATPaseExpert Review of Clinical Pharmacology, 2009
- Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral AdministrationAntimicrobial Agents and Chemotherapy, 2009
- Pharmacology of proton pump inhibitorsCurrent Gastroenterology Reports, 2008
- Guidelines in the management of Helicobacter pylori infection in Japan2003
- Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycinClinical Pharmacology & Therapeutics, 2001